Gastroenterology Update 1997 - Part I;UPDATE GASTROENTEROLOGIE 1997 - TEIL I

Medizinische Klinik

Volumn 93, Issue 2, 1998, Pages 70-80

  Fischbach, Wolfgang ^a   Groß, Volker ^b   Schölmerich, Jürgen ^b   Ell, Christian ^c   Layer, Peter ^d   Fleig, Wolfgang E ^e   Zirngibl, Hubert ^b  

^a KLINIKUM ASCHAFFENBURG   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BOTULINUM TOXIN; BUDESONIDE; CISAPRIDE; CORTICOSTEROID; CYCLOSPORIN; DICLOFENAC; ERYTHROMYCIN; FAMOTIDINE; FLUCONAZOLE; FLUOROURACIL; FUSIDIC ACID; GLUTAMINE; INTERFERON; ITRACONAZOLE; LEVAMISOLE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; OMEPRAZOLE; PREDNISOLONE; PREDNISONE; RANITIDINE; TEICOPLANIN; UNINDEXED DRUG; VANCOMYCIN;

BARRETT ESOPHAGUS; CANDIDIASIS; CROHN DISEASE; DIARRHEA; DYSPEPSIA; ENTEROPATHY; ESOPHAGUS CARCINOMA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PEPTIC ULCER; RESEARCH; REVIEW; STOMACH CARCINOMA; STOMACH SECRETION; ULCERATIVE COLITIS;

HELICOBACTER PYLORI; NEGIBACTERIA;

EID: 0032519527     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03043280     Document Type: Review

References (123)

1. Agreus L, Engstrand L, Svärdsudd K et al. Helicobacter pylori seropositivity among Swedish adults with and without abdominal symptoms. Scand J Gastroenterol 1995;30: 752-7.
2. Agreus L, Svärdsudd K, Nyren O et al. Imtable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time Gastroenterology 1995; 109:671-80.
3. Barbaro G, Barbarini G, Calderon W et al. Fluconazole versus itraconazole for Candida esophagius in acquired immunodeficiency syndrome. Gastroenterology 1996; 111:1169-77.
4. Baretton GB, Diebold J, Christofons G, et al. Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Cancer 77(1996) 255-64
5. Baretton GB, Vogt M, Muller C, et al. Prognostic significance of p53 expression, chromosome 17 copy number, and DNA ploidy in non-metastasized colorectal carcinomas (stages IB and II). Scand J Gastroenterol 1996; 31: 481-9
6. Bate CM, Booth SN, Crowe JP, et al. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux ösophagitis. Gut 1995;36:492-8.
7. Bayerdörffer E, Neubauer A, Rudolph B, et al Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet 1995;354:1591-4.
8. Bayless TM, Tokaver AZ, Polito JM, et al. Crohn's disease: concordance for site and clinical type in affected family members - potential hereditary influences. Gastroenterology 1996;111:573-9.
9. Belluzzi A, Brignola C, Campien M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease N Engl J Med 1996;334:1557-60.
10. Benhattar J, Cerottini JP, Saraga E, et al. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 1996;69:190-2.
11. Bennett MA, Kay EW, Mulcahy H, et al. Ras and p53 in the prediction of survival in Dukes' stage B colorectal carcinoma J Clin Pathol 1995;48:M310-5.
12. Blaser MJ, P.H. Chyou PH, A. Nomura A. Age at establishment of Helicobacter pylori infection and gastric carcinoma, gastric ulcer and duodenal ulcer risk. Cancer Res 1995;55:562-5.
13. Bor-Shyang Sheu, Xi-Zhang Lin, Ching-Yih, Shu-Ghu Shiesh. Is triple therapy beneficial to patients with Helicobacter pylori related nonulcer dyspepsia? Gut 1995; 37:A9.
14. Bouhnik Y, Léman M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine Lancet 1996;347:215-9.
15. Brignola C, Cottone M, Pera A, et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Gastroenterology 1995;108:345-9.
16. Burgh van der A, Dees J, Hop WCJ, et al. Ösophageal cancer is an uncommon cause of death in patients with Barren's ösophagus. Gut 1996;39:5-8.
17. Byrne TA, Persinger RL, Young LS, et al A new treatment for patients with short-bowel syndrome: growth hormone, glutamine, and a modified diet. Ann Surg 1995;222:243-55.
18. Caballero-Plasencia AM, Muros-Navarro MC, Marin-Ruiz JL, et al. Dyspeptic symptoms and gastric emptying of solids in patients with functional dyspepsia. Role of Helicobacter pylori infection. Scand J Gastroenterol 1995;30:745-51.
19. Candy S, Wright J, Gerber M, et al Controlled double blind study of azathioprine in the managment of Crohn's disease. Gut 1995;37:674-8.
20. Caspary WF, Arnold R, Bayerdörffer E, et al. Diagnostik und Therapie der Helicobacter-pylori-Infektion. Z Gastroenterol 1996;34:392-401.
21. Chauhan A, Petch MC, Schofield PM. Cardio-oeosphageal reflex in humans as a mechanism for 'linked angina'. Eur Heart J 1996;17:407-13.
22. Chitkara YK, McCasland KA, Kenefic L, Development and implementation of cost-effective guidelines in the laboratory investigation of diarrhö in a community hospital. Arch Int Med 1996;156:1445-8.
23. Conn HO, Poynard T. Corticosteroids and peptic ulcer; meta-analysis of adverse events during sceroid therapy. J Intern Med 1994;236:619-32.
24. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in Critically III Patients. JAMA 1996;275: 308-14.
25. Cutler AF, Havstad S, Ma CK, et al. Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection. Gastroenterology 1995;109:136-41
26. Dryden MS, Gabb SK, Wright RJE. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin Clin Infect Dis 1996;22:1019-25.
27. Ekström P, Carling L, Wetterhus S, et al Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous nonsteroidal antiinflammatory drug therapy Scand J Gastroenterol 1996;31:753-8.
28. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease N Engl J Med 1995;332:292-7.
29. Field KS, Unterwood M, Brant R, et al Prevalence of gastroösophageal reflux symptoms in asthma CHEST 1996;109:316-22.
30. Fine KD. The prevalence of occult gastrointestinal bleeding in celiac sprue. N Engl J Med 1996;18:1163-7.
31. Funkhouser EM, Sharp GB. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995;76:1116-9.
32. Genta RM, Gurer IE, Graham DY, et al. Adherence of Helicobacter pylori to areas of incomplete intestinal metaplasia in the gastric mucosa. Gastroenterology 1996; 111:1206-11.
33. Giovannucci E, Aschenor A, Rimm EB, et al. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Inrern Med 1995;122:327-34
34. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
35. Glasbrenner B, Malfertheiner P, Nilius M, et al. Prevalence of Helicobacter pylori infection and dyspepsia in young adults in Germany. Z Gastroenterol 1996;34:478-82
36. Goh HS, Yao J, Smith DR. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995;55: 5217-21.
37. Goldstone AR, Quirke P, Dixon MF. Helicobacter pylori infection and gastric cancer. J Pathol 1996;179:129-37.
38. Gorfine SR. Treatment of benigrie anal disease with topical nitroglycerin. Dis Colon Rectum 1995;38:453-7.
39. Gormally SM, Kierce BM, Daly LE, et al. Gastric metaplasia and duodenal ulcer disease in children infected by Helicobacter pylori. Gut 1996;38:513-7.
40. Grant D. Current results of intestinal transplantation. Lancet 1996;347:1801-3.
41. Greenberg GR., Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study. Gastroenterology 1996;110:45-51.
42. Gui D, Cassetta E, Anastasio G, et al. Botulinum toxin for chronic anal fissure. Lancet 1994;344:1127-8.
43. Hamlet A, Olbe L The influence of Hehcobacter pylori infection on postprandial duodenal acid load and duodenal bulb pH in humans. Gastroenterology 1996;111:391-400.
44. Hansson L-E, Nyren O, Hsing AW, et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 1996;335:242-9.
45. Hardcastle JD, Chamberlain JO, Robinson MHE, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.
46. Harding SM, RichterJE, Guzzo MR, et al. Asthma and gastroösophageal reflux: Acid suppressive therapy improves asthma outcome. Am J Med 1996;100:395-105.
47. Harria AW, Gummett PA, Misiewicz JJ, et al. Eradication of Helicobacter pylori in patients with duodenal ulcer lowers basal and peak acid outputs to gastrin releasing peptide and pentagastrin. Gut 1996;38:663-7.
48. Harris AW, Gummett PA, Walker MM, et al. Relation between gastric acid output, Helicobacter pylori, and gastric metaplasia in the duodenal bulb Gut 1996;39:513-20.
49. Hayashi N, Ito I, Yanagisawa A, et al. Genetic diagnosis of lymphnode metastasis in colorectal cancer. Lancet 1995; 345:1257-9.
50. Heinemann EF, Zahm H, McLaughlin JK, et al. Increased risk of colorectal cancer among smokers: results of a 26-year follow-up of US veterans and a review, Int J Cancer 1995;59:728-38
51. Henry D, Lim LL-Y, Rodriguez LAG, et al. Variability in risk of gastrointestinal complications with individual nonsterodial antunflammatory drugs: results of a collaborative metaanalysis BMJ 1996;312:1563-6.
52. Hill M, Norman A, Cunningharn D, et al. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 1995; 13:1297-1302
53. Imperiale TF, Speroff T.R. Bebul RC, et al. A cost analysis of alternative treatments for duodenal ulcer. Ann Intern Med 1996;123:665-72.
54. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-44
55. Kahnlas PJ. Gastroosophageal reflux disease. JAMA 1996;276:983-8
56. Kanda T, Fujii H, Murakami H, et al. Intestinal fatty acidbinding protein is a useful diagnostic marker for mesenteric infarction in humans. Gastroenterology 1996;110:339-43.
57. Khulusi S, Badve S, Patel P, et al Pathogenesis of gastric metaplasia of the human duodenum: role of Helicobacter pylori, gastric acid, and ulceration. Gastroenterology 1996;110:452-8.
58. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood-rest. Lancer 1996;348:1467-71.
59. Kuipers EJ, Lundell DL, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in parients with reflux esophagitis treated with orneprazole or fundoplication. N Engl J Med 1996;334:18-22.
60. Labenz J, Tillenburg B, Peitz U. et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110: 725-32.
61. Lanas AI, Remacha B, Esteva F, et al. Risk factors associated with refractory peptic ulcers. Gastroenterology 1995;109:1124-33.
62. Lankisch PG, Schramm AM, Peterson A, et al. Diagnostic intervals for recognizing celiac disease. Z Gastroenterol 1996;34:473-7
63. Laukka MA, Cameron J, Schei AJ. Gaströsophageal reflux and chronic cough: Which comes first? J Clin Gastroenterol 1994;19:100-4.
64. Layer P, Brambs H-J, Ell C, et al. Update Gastroenterologie 1995 - Teil I. Med Klin 1995;90:701-8.
65. Layer P, Brambs H-J, Ell C, et al Update Gastroenterologie 1995 - Teil II. Med Klin 1996;91:20-7.
66. Locke GR, Talley NJ, Carpenter HA, et al. Changes in the site and histology-specific incidence of gastric cancer during a 50-year period. Gastroenterology 1995;109 1750-6.
67. Löfberg R, Danielsson A, Subr O, et al. Oral budesomde versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996;110: 1713-8.
68. Lôfberg R., Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut 39(1996) 82-86
69. Maxton DG, Morris J, Whorwell PJ. Selective 5-hydroxytryptamine antagonism:a role in irritable bowel syndrome and functional dyspepsia? Aliment Pharm Ther 1996;10:595-9.
70. McDougall NI, Johnston BT, Kee F et al. Natural history of reflux osophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut 1996;38:481-6.
71. McFarlane XA., Bhalla AK, Robertson DAF. Effect of a gluten free dier on osteopenia in adults with newly diagnosed coeliac disease. Gut 1996;39:180-4.
72. McLeod RS, Wolff BG, Steinhart AH, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 1995;109:404-13.
73. Modigliani R, Colombel JF, Dupas JL, et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance. Gastroenterology 1996;110:688-93.
74. Moertel CG, Flerning TR, MacDonald JS, et al. Fluorourscil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-6.
75. Moser R, Hausmaninger H, Ludwig H, et al. 5-Fluorouracil and folinic acid with or without interferon in the treatment of metastatic colorectal cancer: preliminary results of a multicenter prospective randomized phase-III trial. Onkologie 1995;18:131-5.
76. Muller-Lissner SA, Bavanan Constipation Study Group, Cisapride in chronic idiopathic constipation: Can the colon be re-educated? Eur J Gastroenterol Hepatol 1995; 7:69-73.
77. Murray FE, Hudson N, Atherton JC, et al. Comparison of effects of calcium carbasalate and aspirin on gastroduodenal mucosal damage in human volunteers. Gut 1996;38:11-4.
78. Muta H, Nogucchi M, Perucho M, et al. Clinical implications of microsatellite instability in colorectal cancer. Cancer 1996;77:265-70.
79. Olbe L., Hamlet A, Dalenbäck J, et al. A mechanism by which Helicobacter pylori infection of the antruni contributes to the development of duodenal ulcer. Gastroenterology 1996;110:1386-94.
80. Oren R, Arber N, Odes S, et al Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial Gastroenterology 1996;110:1416-21.
81. Panos MZ, Walt RP, Stevenson C, et al. Rising death rate from non-malignant disease of the ösophagus (NMOD) in England and Wales. Gut 1995;36:488-91.
82. Parsonnet J Helicobacter pylori in the stomach - a paradox uninasked. N Engl J Med 1996;335:278-80.
83. Pasricha PJ, Ravich WJ, Hendry TR, et al. Intrasphincteric botulinum toxin for the treatment of achalasi. N Engl J Med 1995;322:774-8.
84. Penston JG, Pounder RE. A survey of dyspepsia in Great Britain. Alunent Pharmacol Ther 1996;10:83-9.
85. Persson PG, Bernell O, Leijonmarck CE, et al. Survival and cause-specific mortality of inflammatory bowel disease: a population-based cohort study. Gastroenterology 1996;110:1339-45.
86. Pitkäjärvi T, Kujanne E, Silliantaka I, Lurnio J. Norfloxacin and salmonella excretion in acute gastroenteritis - a 6-month follow-up study. Scand J Infect Dis 1996;28: 177-80.
87. Porro GB, Parente V, Imbesi, et al. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users Response to omeprazole dual therapy. Gut 1996;39:22-6.
88. Raskin JB, White H, Jaszewski R, et al. Misoproscol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol 1996;9:223-7.
89. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal antiinflammatory drug -induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995;123:334-50.
90. Rensch MJ, Merenich JA, Lieberman M, et al. Glutensensitive enteropathy in patients with insulin-dependent diabetes mellitus. Ann Int Med 1996;124:564-77.
91. Roggero E, Zucca E, Pinotti G, et al Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa associated lymphoid tissue. Ann Intern Med 1995;122:767-9.
92. Rosenstock SJ, Andersen LP, Kay L, et al. Helicobacter pylori and gastrointestinal symptoms Is there a relationship? Gut 1995;37:A193.
93. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection Gastroenterology 1995; 108:1617-21.
94. Saltissi S. Cardio-osophageal reflux and 'linked angina'-is the way to a man's (or woman's) heart through the stomach? Eur Heart J 1996;17:329-31.
95. Sandborn WJ, Van Os EC, Zins BJ, et al. An intravenous loading dose of azathioprine decreases the time of response in patients with Crohn's disease. Gastroenterology 1996;109:1808-17.
96. Savanno V, Mela GS, Zentilin P, et al. Circadian gastric acidity in Helicobacter pylori positive ulcer patients with and without gastric metaplasia in the duodenum. Gut 1996;39:508-12.
97. Scheppach W, German-Austria SACFA Study Group. Treatment of distal ulcerative colins with short-chain fatty acid enemas Dig Dis Sci 1996;41:2254-9.
98. Shaker R, Milbrath M, Ren J, et al Esophagoryngeal distribution of refluxed gastric acid in patients with reflux laryngitis. Gastroenterology 1995;109:1575-82.
99. Sharma SS, Bhargava N, Mathur SC. Effect of oral erythromycin on colonit transit in patients with idiopathic constipation. Dig Dis Sci 1995;40:2446-9.
100. Silverstein MD, Petterson T, Talley NJ, Initial endoscopy or empirical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterology 1996;110:72-83.
101. Simon DM, Cello JP, Valenzuela J. et al Multicenter trial of octrotide in patients with refractory acquired immunodeficiency syndrome-associated diarrhöa. Gastroenterology 1995;108:1753-60
102. Sipponen P, Kosunen TU, Samloff IM, et al. Rate of Helicobater pylori acpuisition among Finnish adults. Scand J Gastroenterol 1996;31:229-32
103. Slattery J, Warlow CP, Shorrock CJ, et al. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin - analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1996;37:509-11
104. Sonnenberg A., Townsend WF. Costs of duodenal ulcer therapy with antibiotics. Arch Intern Med 1995; 155: 922-8.
105. Stange EF, Modighani R, Pena AS, et al European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. Gastroenterology 1995;109:774-82.
106. Stefanini GF, Saggioro A, Alvisi V, et al Oral cromoly sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. Scand J Gastroenterol 1995;30:535-41
107. Sung JJY, Chung S, Ling TKW, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995;332:139-42.
108. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duoderial ulcers caused by nonsteroidal antiinflammatory drugs. N Engl Med 1996;334:1435-9.
109. Thomas GAO, Rhodes J, Ragunath K, et al. Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis. Eur J Gastroenterol Hepatol 1996;8:769-76.
110. Thompson NP, Driscoll R, Pounder RE, et al. Genetics versus environment in inflammatory bowel disease: results of a British twin study. BMJ 1996;312:95-6.
111. Vaezi MF, Richter JE. Role of acid and duodenogastrosophageal reflux in gastroösophageal reflux disease Gastroenterology 1996;11:1192-9
112. Van Dullemen H, Van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease with antitumor necrosis factor chimeric monoclonal antibody(cA2). Gastroenterology 1995;109:129-35.
113. Vazquez H, Cabanne A, Sugai E, et al. Serological markers identify histologically latent coeliac disease among firstdegree relatives. Eur J Gastroenterol Hepatol 1996;8: 15-21.
114. Verdu EF, Armstrong D, Idström J-P, et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995;37: 743-8
115. Verdù EF, Fraser R, Tiberio D, et al. Prevalence of Helicobacter pylori infection and chronic dyspetic symptoms among immigrants from developing countries and people born in industrialized countries. Digestion 1996; 57:180-5.
116. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-10.
117. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-7
118. Waring JP, Lacayo L, Hunter J, Katz E et al Chronic cough and hoarseness in patients with severe gastroosophageal reflux disease Diagnosis and response to therapy Dig Dis Sci 1995;40:1093-7.
119. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-30.
120. Wenisch C, B. Parschalk, M Hasenhündl, et al.: Comparison of vancornycin, teicoplanin, metronidazole, and fusidic acid for the treatment of clostridium difficile-associated diarrhea. Clin Infect Dis 1996;22:813-8
121. Wilcox MH, Howe R. Diarrhöa caused by clostridium difficile: response time for treatment with metronida-zole and vancomycin. J Antimicrob Chemother 1995;36:673-9.
122. Wilke HJ, Fink U Multimodal therapy for adenocarcinoma of the esophagus and esophagogastric junction. N Engl J Med 1996;335:509-10.
123. Yousfi MM, El-Zimaity HMT, Cole RA, et al. Detection of Helicobacter pylori by rapid urease tests: Is biopsy size a critical variable? Gastrointest Endosc 1996;43:222-4.